AGM/EGMApr 27, 2026, 04:34 PM
SPRO Annual Meeting to Vote on Share Increase, Stock Plan
AI Summary
Spero Therapeutics, Inc. will hold its 2026 annual meeting of stockholders virtually on June 23, 2026. Stockholders will vote on several key proposals, including the election of two directors, ratification of the independent auditor, and an advisory vote on executive compensation. Most notably, the company seeks approval to double its authorized common stock from 120 million to 240 million shares and to adopt a new 2026 Stock Incentive Plan.
Key Highlights
- Annual meeting scheduled for June 23, 2026, at 9:00 a.m. Eastern Time, virtually.
- Proposal to increase authorized common stock from 120,000,000 to 240,000,000 shares.
- Proposal to approve the Spero Therapeutics, Inc. 2026 Stock Incentive Plan.
- Election of two Class III directors: Milind Deshpande, Ph.D. and Kathleen Tregoning.
- Ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year 2026.
- Advisory vote on the compensation of named executive officers.
- Record date for voting is April 24, 2026, with 57,901,493 shares outstanding.
Price Impact
More from SPRO
USFDA1d ago, 12:37 PM
Spero Therapeutics: FDA Approves First Oral Carbapenem Antibiotic Utebzi
Quarterly ResultMay 13, 4:12 PM
Spero Therapeutics Q1 Net Loss Halved to $7.2M; Operating Cash Flow Positive
Quarterly ResultMay 13, 4:08 PM
Spero Therapeutics Q1 Net Loss $7.2M; Tebipenem HBr FDA Decision June 18